# Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

> **NCT04312607** · — · UNKNOWN · sponsor: **Safaa AA Khaled** · enrollment: 80 (estimated)

## Conditions studied

- Myeloproliferative Neoplasm

## Interventions

- **DIAGNOSTIC_TEST:** BCR-ABL gene PCR

## Key facts

- **NCT ID:** NCT04312607
- **Lead sponsor:** Safaa AA Khaled
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2021-08-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04312607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04312607, "Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04312607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*